CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

CRISPR technology, targeting genetic diseases and cancer, may bring major biotech stock growth. CRISPR Therapeutics and Intellia show progress with clinical trials and big pharma partnerships.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

“It’s a little scary, quite honestly,” says Dr. Jennifer Doudna, who helped develop CRISPR gene-editing technology. By David Marchese It’s entirely possible, maybe even likely, that during some slow ...

CRISPR ETFs invest in companies perfecting gene-editing technology, potentially key for future disease treatments. Top CRISPR ETFs include ARK Genomic Revolution, Global X Genomics, and WisdomTree ...